Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Secondary Hyperparathyroidism Due to Renal Causes Clear all

Completed Phase 4 Interventional Results available

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

NCT03588884

View directory record Official record

Conditions: Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
Interventions: Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin

Source: ClinicalTrials.gov public record

Updated Dec 8, 2022 · Synced May 21, 2026, 11:47 PM EDT

Terminated Phase 2 Interventional Results available

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

NCT03602261

View directory record Official record

Conditions: Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
Interventions: Calcifediol Oral Capsule, Placebo oral capsule; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 18
States / cities: Peoria, Arizona • Phoenix, Arizona • Cypress, California + 13 more

Source: ClinicalTrials.gov public record

Updated Apr 2, 2026 · Synced May 21, 2026, 11:47 PM EDT